A., Harsoyo, P
Los agonistas del receptor GLP-1 (GLP-1 RAs) como liraglutida, semaglutida o exenatida son medicamentos desarrollados para imitar la accin del GLP-1 que producimos, pero con estructuras qumicas modificadas para mejorar su vida media y eficacia
In type 2 diabetes, much of the evidence comes from post hoc analyses of trials that primarily examine the effects of single drugs compared with placebo
The following parameters were tested: total motility (TM, %), progressive motility (PM, %), linearity (LIN, %), average path velocity (VAP, m/s), straight line velocity (VSL, m/s), curvilinear velocity (VCL, m/s), beat cross frequency (BCF, Hz)
Although rates of acute pancreatitis have been low and similar between GLP-1 agonists and placebo in studies, caution is still warranted since acute pancreatitis carries a risk of recurrencewhich can turn into chronic pancreatitiswhich can increase risk of pancreatic cancer
These are all part of a class of drugs called GLP-1 agonists, and they're making waves in how we manage conditions like type 2 diabetes and obesity